POSC359 The Real-World Observational Prospective Study of Health Outcomes with Dulaglutide & Liraglutide in Type 2 Diabetes Patients (TROPHIES): Patient Reported Outcomes at 12-Months

K Boye,J Lebrec,H Sapin,B Guerci,F Giorgino,M Füchtenbusch,E Heitmann,M Orsini Federici,A Dib,Le García-Pérez

doi:10.1016/j.jval.2021.11.1184

POSC359 The Real-World Observational Prospective Study of Health Outcomes with Dulaglutide & Liraglutide in Type 2 Diabetes Patients (TROPHIES): Patient Reported Outcomes at 12-Months

K Boye, J Lebrec + Show 8 more

Open Access

https://doi.org/10.1016/j.jval.2021.11.1184

Copy DOI

Journal: Value in health : the journal of the International Society for Pharmacoeconomics and Outcomes Research	Publication Date: Jan 1, 2022
License type: elsevier-specific: oa user license

Affiliation: Eli Lilly (United States), Centre Hospitalier Universitaire de Nancy, Polytechnic University of Bari, University of Bari Aldo Moro, München Klinik, Eli Lilly (Germany)

#Injectable Glucagon-like Peptide-1 Receptor Agonist #Patient-reported Outcome + Show 8 more

Abstract
Full-Text PDF
Similar Papers

Abstract

Patient-reported outcome (PRO) measures provide information that complement clinical data. Studies assessing PRO measures in people living with T2D who initiate injectable glucagon-like peptide-1 receptor agonist (GLP-1 RA) medication in routine clinical practice are limited. To better understand the perspectives of people living with T2D regarding their overall health, treatment/device satisfaction, and quality of life and work, here we describe perspectives of participants at the 12-month time-point of TROPHIES.

Full Text